Morgan Stanley Downgrades Alector: Here's What You Need To Know

Morgan Stanley Downgrades Alector: Here's What You Need To Know

Morgan Stanley downgraded its rating of Alector ALEC to Equal-Weight with a price target of $13.00, changing its price target from $27.00 to $13.00.

Shares of Alector are trading down 12.47% over the last 24 hours, at $9.62 per share.

A move to $13.00 would account for a 35.14% increase from the current share price.

About Alector

Alector Inc is a clinical stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies which are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline product inlcude AL001, AL002, AL003, and AL101.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Posted In: BZI-AAR-UPDATEAnalyst Ratings